P150 - ECE_1744 - Empagliflozin for the treatment of postprandial hypoglycaemia—a randomized placebo-controlled superiority study and meta-analysis
Abstract
Postbariatric hypoglycaemia (PBH) significantly impairs quality of life and remains difficult to treat, with current therapies offering limited benefit. Although empagliflozin reduced hypoglycaemic episodes in an acute trial, its longer-term effects on hypoglycaemia and quality of life are unknown. We hypothesised that empagliflozin would reduce hypoglycaemic episodes and improve quality of life in individuals with PBH.
In this multicentre, randomized, double-blind, placebo-controlled trial, 40 adults (18-75 years) with frequent PBH were assigned to empagliflozin 10 mg daily or placebo for 28 days. Primary outcomes were changes in SF-36 mental and physical health scores and frequency of hypoglycaemic events measured by blinded continuous glucose monitoring (CGM). Secondary outcomes included patient-reported symptoms, metabolic measures, and safety. Analyses were performed in the full analysis set with per-protocol sensitivity analyses. A post-hoc random-effects meta-analysis combined these findings with prior studies.
Empagliflozin did not improve physical or mental quality-of-life scores compared with placebo. The number of CGM-detected hypoglycaemic episodes tended to be higher with empagliflozin (P = .054), supported by sensitivity analyses showing an increased risk (incidence rate ratio 1·86, 95% CI 1·07-3·23). Time spent in hypoglycaemia (<3·0 mmol/L) was significantly greater with empagliflozin (0·90% vs 0·40%). Despite this, participants reported fewer symptomatic…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 40 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.